- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01392612
Erythropoietin and Platelet Activation Markers
The Effect of Erythropoietin on Platelet Activation Markers: a Prospective Study in Healthy Volunteers
We hypothesized that the effect of erythropoietin may be reflected by changes in thromboxane B2 (TXB2) and endothelial cell function.
Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 Units per kg). Biomarker levels were assessed at baseline and 4, 24, 48 and 72 hours after administration.
Study Overview
Detailed Description
Introduction: Erythropoietin (EPO) enhances formation of red blood cells and also affects thrombopoiesis and platelet function. We hypothesized that the effect of erythropoietin may be reflected by changes in thromboxane B2 (TXB2) and endothelial cell function.
Methods: Six male and six female subjects received recombinant human epoetin alpha (Erypo®) intravenously (300 Units per kg). Biomarker levels were assessed at baseline and 4, 24, 48 and 72 hours after administration.
Results: Epoetin alpha increased TXB2 levels, which reached significance at 48h (2.5- fold increase: 6.6±5ng/mL vs. 15±9ng/mL; p=0.044) and remained at that level at 72h. In line, epoetin alpha increased E-selectin levels by 25% already at 24h (39±21ng/ml vs. 49±26ng/ml; p<0.001) and stayed at this level until 72h (p<0.001). The raise in platelet activation markers corresponded with a 2-fold increase in reticulocyte count (81±17G/L vs. 43±10G/L; p<0.001) and a 9% increase in platelet count at 72h (224±45G/L vs. 244±52G/L; p=0.005). Thrombomodulin and von Willebrand factor concentrations were not significantly altered by epoetin alpha. Interestingly, gender differences in the baseline levels of E-selectin and thrombomodulin were observed. E-selectin and thrombomodulin levels were doubled in men compared to women (51±24ng/mL and 28±10ng/mL; p=0.025 and 30±5ng/mL vs. 16±5ng/mL; p=0.002, respectively).
Conclusion: Epoetin alpha increases levels of platelet activation markers. Further studies are needed to investigate whether measurement of TXB2 or E-selectin levels might be useful for estimation of thromboembolic risk during EPO-therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female volunteers.
- Age between 18-40 years.
- Body mass index 17-27.
- Normal haemoglobin levels (Hb males 13.5-18g/dL, females 12-16g/dL).
- Reticulocyte count within reference values (32-110G/L).
- S-Iron within reference values (males 60-150µg/dl, females 40-150µg/dL).
- Serum ferritin within reference values (females 10-140µg/L, males 20-280µg/L).
- CRP within reference values (<1,0mg/dL).
- Signed informed consent.
- Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant for this study.
- Woman of child bearing potential must agree to practice effective barrier methods for birth control.
Exclusion Criteria:
- Smoking.
- Regular use of medication and food supplements containing iron.
- Abuse of alcoholic beverages and drugs.
- Participation in a clinical trial in the 3 weeks preceding the study.
- Foreseen inability to attend to scheduled study visits.
- Deficiency in folate (<3.4nmol/L) or vitamin B12 (<118pmol/L) (reevaluation after supplementation is allowed).
- Evidence of hypertension, pathologic hyperglycemia, hyperlipidemia. AST and/or ALAT > 3xULN (AST males > 105U/L, females >93U/; ALAT males > 135U/L, females >102U/L).
- Symptoms of a clinically relevant illness during 3 weeks prior the first study day.
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of erythropoietin.
- Blood donation during the previous 3 weeks prior to the first study day.
- History of hypersensitivity erythropoietin.
- Pregnancy or lactation period.
- Any medical condition that, in the opinion of the investigator, would interfere with safety of the subject or interference of the objectives of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Erythropoietin
all subjects received epo iv.
|
Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight.
Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in platelet activation markers
Time Frame: platelet activation markers were measured 4, 24, 48 and 72 hours after administration of iv EPO
|
We wanted to examine whether levels of platelet activation markers change after administration of EPO and if they do, in which time frame it happens.
|
platelet activation markers were measured 4, 24, 48 and 72 hours after administration of iv EPO
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in erythropoietin levels
Time Frame: erythropoietin levels were measured 4, 24, 48 and 72 hours after administration
|
We wanted to examine erythropoietin-levels after administration of EPO at mentioned time points.
|
erythropoietin levels were measured 4, 24, 48 and 72 hours after administration
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Wolzt, Prof., Medical University of Vienna
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPO1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on erythropoietin
-
University of CambridgeHoffmann-La Roche; Roche Foundation of Anemia Research (RoFAR, Switzerland)CompletedAneurysmal Subarachnoid HemorrhageUnited Kingdom
-
Bundang CHA HospitalLG Life SciencesCompleted
-
Chugai PharmaceuticalCompletedChemotherapy Induced Anemia
-
Angde Biotech Pharmaceutical Co., Ltd.Recruiting
-
NICHD Neonatal Research NetworkNational Center for Research Resources (NCRR)CompletedAnemia, Neonatal | Infant, Small for Gestational Age | Infant, Premature | Infant, Low Birth Weight | Infant, NewbornUnited States
-
Fatih Sultan Mehmet Training and Research HospitalDr. Lutfi Kirdar Kartal Training and Research HospitalCompleted
-
Shenyang Sunshine Pharmaceutical Co., LTD.Unknown
-
VA Office of Research and DevelopmentTerminatedAtherosclerosis | Anemia | CKD | CardiovascularUnited States
-
Tianjin SinoBiotech Ltd.Completed
-
Shenzhen Second People's HospitalRecruiting